LNTH

Qué hace la empresa

Lantheus, headquartered in Billerica, Massachusetts, is a company in the radiopharmaceuticals business. It has strategic partnerships with Bayer, Novartis, Regeneron as well as GE Healthcare and Siemens Healthineers.

Fuente: Wikipedia (CC BY-SA 4.0) · copiada el 3 sept 2026 · puede no reflejar cambios recientes.

Esta descripción solo está disponible en inglés.

Cada tema lo asigna un clasificador sobre el documento completo; los fragmentos muestran dónde lo detectó y no siempre bastan para comprobarlo. Abre el documento para leerlo entero.

• 2026-05-07ampliación de capital o diluciónrecienteVer expediente ↗
  “…fiscal years. The Company prospectively adopted ASU 2024-04 as of January 1, 2026. The adoption did not have a material impact on…”
  +1 pasaje más del mismo documento

  • “…are generally secured by first priority liens over substantially all of the assets of each of Lantheus Medical, Lantheus Holdings,…”
• 2026-05-07retorno de capital (recompras/dividendos)recienteVer expediente ↗
  “…and commercialize Lantheus’ piflufolastat F-18 PET imaging agent (marketed in the United States as PYLARIFY) in Japan for…”
  +1 pasaje más del mismo documento

  • “…and commercialize Lantheus’ piflufolastat F-18 PET imaging agent (marketed in the United States as PYLARIFY) in Japan for prostate…”
• 2026-05-07fusión o adquisiciónrecienteVer expediente ↗
  “…consolidated financial statements herein. Acquisition of Evergreen Theragnostics, Inc. On April 1, 2025, we acquired all the…”
  +1 pasaje más del mismo documento

  • “…Acquisition of Evergreen Theragnostics, Inc. On April 1, 2025, we acquired all the issued and outstanding shares of Evergreen by…”
• 2026-05-07contrasplit (reverse split)recienteVer expediente ↗
  “…tumors, and an option to co-develop certain early-stage therapeutic candidates targeting prostate cancer using…”
  +1 pasaje más del mismo documento

  • “…of neuroendocrine tumors, and an option to co-develop certain early-stage therapeutic candidates targeting prostate cancer using…”
• 2026-02-26ampliación de capital o diluciónrecienteVer expediente ↗
  “…or prevent a decrease in, the market price of our common stock, although there can be no assurance that an increase, or prevention of…”
  +1 pasaje más del mismo documento

  • “…in a different manner, which could negatively impact the market price of our common stock. The conditional conversion feature…”
• 2026-02-26retorno de capital (recompras/dividendos)recienteVer expediente ↗
  “…and PMF sites to ensure a smooth rollout of the new formulation, including providing clear guidance on ordering, handling, and…”
  +1 pasaje más del mismo documento

  • “…and PMF sites to ensure a smooth rollout of the new formulation, including providing clear guidance on ordering, handling, and…”
• 2026-02-26fusión o adquisiciónrecienteVer expediente ↗
  “…Life Molecular to Lantheus Biosciences Ltd. Acquisition of Evergreen Theragnostics, Inc. On April 1, 2025, we acquired all the…”
  +1 pasaje más del mismo documento

  • “…Acquisition of Evergreen Theragnostics, Inc. On April 1, 2025, we acquired all the issued and outstanding shares of Evergreen by…”
• 2026-02-26contrasplit (reverse split)recienteVer expediente ↗
  “…to Perspective, and the parties entered into a transition services arrangement pursuant to which we provided to Perspective…”
  +1 pasaje más del mismo documento

  • “…to Perspective, and the parties entered into a transition services arrangement pursuant to which we provided to Perspective…”

Fragmentos originales de documentos SEC, sin traducir. No es asesoramiento ni una predicción.